Sputnik V makers say Covid-19 vaccine is 95% effective, will cost under Rs 750
First Published Nov 24, 2020, 4:37 PM IST
Russia's Sputnik V coronavirus vaccine is 95 percent effective according to a second interim analysis of clinical trial data. Preliminary data from volunteers obtained 42 days after the first dose (corresponds with 21 days after the second dose) indicates an efficacy of the vaccine above 95%.

Preliminary data from volunteers obtained 42 days after the first dose (corresponds with 21 days after the second dose) indicates an efficacy of the vaccine above 95%.

The Sputnik V vaccine is based on a well-studied human adenoviral vector platform that has proven safe and effective with no long-term side effects in more than 250 clinical trials globally conducted during the past two decades -- while the history of the use of human adenoviruses in vaccine development began in 1953. More than 100,000 people have received approved and registered drugs based on human adenoviral vectors.